Published Date: 16 Feb 2023
How is the SARS-CoV-2 mRNA antibody similar to the P.1 gamma strain and other strains?
Read Full NewsThe ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.
Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.
FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.
Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.
A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.
The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.
Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa
1.
Medicaid expansion tied to smaller declines in early-stage cancer detection
2.
Cancer Patients Are Receiving More and More Stupid Immunotherapy.
3.
Mapping lifelong chronic health risks for childhood cancer survivors
4.
Sickle Cell Disease Drug Pulled From Global Markets
5.
Survival rates for incurable larynx cancer investigated for first time
1.
Surprising Symptoms of Prostate Cancer: What You Need to Know
2.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
3.
Exploring the Unknown: Unveiling the Mysteries of GIST Tumors
4.
The Power of White Blood Cells: How They Help Keep Us Healthy
5.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation